Journal
BLOOD
Volume 142, Issue 9, Pages 753-754Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2023021224
Keywords
-
Categories
Ask authors/readers for more resources
This study demonstrates the potential effectiveness of targeting the NF-kappa B pathway with oral dimethyl fumarate (DMF) in certain patients with mycosis fungoides and Sezary syndrome (MF/SS).
In this issue of Blood, Nicolay et al demonstrate that targeting the NF-kappa B pathway with oral dimethyl fumarate (DMF) may be effective in certain patients with mycosis fungoides and Sezary syndrome (MF/SS).(1) Building on their preclinical data demonstrating that DMF restores apoptosis sensitivity among malignant cells,2 the authors demonstrate the activity of single-agent DMF in a heterogeneous population of patients with relapsed or refractory stage IB-IV MF/SS in this phase 2 multicenter clinical trial.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available